1. 374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors. (10th December 2020) Authors: Mahalingam, Devalingam; Harb, Wael; Patnaik, Amita; Ulahannan, Susanna; Mahdi, Haider; Ahluwalia, Manmeet; Patel, Manish; Dowlati, Afshin; Bullock, Andrea; Wen, Patrick; Pant, Shubham; Mulcahy, Mary; Guttendorf, Robert; Vaickus, Lou; Wang, Suming; Crochiere, Marsha; Vincent, Melanie; Cieslewicz, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors. (9th November 2020) Authors: Mahalingam, Devalingam; Harb, Wael; Patnaik, Amita; Ulahannan, Susanna; Mahdi, Haider; Ahluwalia, Manmeet; Patel, Manish; Dowlati, Afshin; Bullock, Andrea; Wen, Patrick; Pant, Shubham; Mulcahy, Mary; Guttendorf, Robert; Vaickus, Lou; Wang, Suming; Crochiere, Marsha; Vincent, Melanie; Cieslewicz, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A399 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Issue 13 (10th November 2021) Authors: Sweet, Kendra; Bhatnagar, Bhavana; Döhner, Hartmut; Donnellan, Will; Frankfurt, Olga; Heuser, Michael; Kota, Vamsi; Liu, Hongtao; Raffoux, Emmanuel; Roboz, Gail J.; Röllig, Christoph; Showel, Margaret M.; Strickland, Stephen A.; Vives, Susana; Tang, Shijie; Unger, Thaddeus J.; Joshi, Anita; Shen,... Journal: Leukemia & lymphoma Issue: Volume 62:Issue 13(2021) Page Start: 3192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CTIM-06. CLINICAL EFFICACY AND BIOMARKER ASSESSMENT OF VT1021, A CD36/CD47 DUAL-TARGETING AGENT, IN RECURRENT GLIOBLASTOMA. (12th November 2021) Authors: Ahluwalia, Manmeet; Battiste, James; Bockorny, Bruno; Bullock, Andrea; Patel, Manish; Wen, Patrick; Shepard, Dale; Vaickus, Lou; Vincent, Melanie; Chen, Jian jenny; Wang, Suming; Watnick, Randolph; Crochiere, Marsha; Cieslewicz, Michael; Watnick, Jing Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds. Issue 1 (December 2015) Authors: Crochiere, Marsha; Kashyap, Trinayan; Kalid, Ori; Shechter, Sharon; Klebanov, Boris; Senapedis, William; Saint-Martin, Jean-Richard; Landesman, Yosef Journal: BMC cancer Issue: Volume 15:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing. Issue 1 (22nd January 2015) Authors: Neggers, Jasper E.; Vercruysse, Thomas; Jacquemyn, Maarten; Vanstreels, Els; Baloglu, Erkan; Shacham, Sharon; Crochiere, Marsha; Landesman, Yosef; Daelemans, Dirk Journal: Chemistry & biology Issue: Volume 22:Issue 1(2015) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing. Issue 1 (22nd January 2015) Authors: Neggers, Jasper E.; Vercruysse, Thomas; Jacquemyn, Maarten; Vanstreels, Els; Baloglu, Erkan; Shacham, Sharon; Crochiere, Marsha; Landesman, Yosef; Daelemans, Dirk Journal: Chemistry & biology Issue: Volume 22:Issue 1(2015) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma. (4th November 2015) Authors: Farren, Matthew R; Shakya, Reena; Hennessey, Rebecca; Mace, Thomas; Yang, Jennifer; Elnaggar, Omar; Young, Gregory; Landesman, Yosef; Carlson, Robert; Elloul, Sivan; Crochiere, Marsha; Burd, Christin; Lesinski, Gregory Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma. Issue 2 (December 2015) Authors: Farren, Matthew; Shakya, Reena; Hennessey, Rebecca; Mace, Thomas; Yang, Jennifer; Elnaggar, Omar; Young, Gregory; Landesman, Yosef; Carlson, Robert; Elloul, Sivan; Crochiere, Marsha; Burd, Christin; Lesinski, Gregory Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗